Liraglutid kann periphere Arterienerkrankungen bei Typ-2-Diabetes lindern

NEW TOP LINE:

In individuals with type 2 diabetes (T2D) and peripheral arterial vascular disease (pAVK), Liraglutide significantly increased peripheral blood flow over a 6-month period compared to conventional treatment of cardiovascular risk factors.

METHODOLOGY:

• An open, randomized clinical study conducted between February 1, 2021, and June 30, 2022, with a final follow-up on December 30, 2022, at a single center in Naples, Italy.
• A total of 55 individuals with T2D, pAVK, and transcutaneous oxygen pressure (TcPO₂) between 30 and 49 mmHg were randomized to receive either a subcutaneous administration of 1.8 mg Liraglutide (n = 27) or conventional treatment of cardiovascular risk factors (n = 28) over a 6-month period.

RESULTS:

• An increase of ≥10% in TcPO₂ from baseline occurred in 89% (n = 24) of participants randomized to Liraglutide compared to 46% (n = 13) of control participants (relative risk 1.91; P < .001).
• TcPO₂ increased in both groups over time but was significantly higher in the Liraglutide group after 6 months (estimated treatment difference: 11.2 mmHg; P < .001).
• After 6 months, C-reactive protein (−0.4 mg/dl; P = .02), urinary albumin excretion rate (–119.4 mg/g; P < .003), and 6-minute walk distance (25.1 m; P < .001) also improved.

CLINICAL IMPLICATIONS:

“The administration of Liraglutide improved peripheral blood flow in individuals with T2D and pAVK, suggesting it could prevent the clinical progression of pAVK,” the authors wrote.

SOURCE:

The study was conducted by Paola Caruso, PhD, from the Department of Endocrinology and Metabolic Diseases at the University of Campania “Luigi Vanvitelli” and colleagues, and was published online on March 12, 2024, in JAMA Network Open.

LIMITATIONS:

The study had a relatively short follow-up time, an open design (although the researchers were blinded), and a small sample size.

DISCLOSURE:

The study was partially funded by the PhD Program in Translational Medicine at the University of Campania “Luigi Vanvitelli,” Naples, Italy (to Paola Caruso). Three co-authors reported disclosures to manufacturers of diabetes products.